Grafeel
Filgrastim
Pre-filled syringe: 300 mcg | Vial: 300 mcg
Therapeutic Areas
Haematology , Oncology
Indications
- Chemotherapy Induced-Neutropenia
- Neutropenia
Shelf Life
3 years
Launched Year
2001
Available in
8 Countries
What is Grafeel?
Grafeel (Filgrastim) is Dr. Reddy’s Biologics’ first biosimilar product that was launched in 2001. Grafeel is used to treat neutropenia (low white blood cells) that is caused by chemotherapy. Filgrastim helps the bone marrow to make new white blood cells.
Storage Conditions
2-8 degrees Celsius (refrigerate), Do not freeze.
Presentation
Vial containing drug + PFS containing drug
Route of Administration:
Subcutaneous (SC) (upon prescription only and administered by a healthcare provider.)
Indications
How Filgrastim works?
Mechanism of Action
Grafeel contains filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils. Its mechanism of action involves binding to G-CSF receptors on precursor cells in the bone marrow, activating the JAK-STAT signaling pathway. This leads to the proliferation, differentiation, and maturation of neutrophils, which are then released into the bloodstream. By increasing neutrophil counts, Grafeel helps reduce the risk of infections, especially in patients undergoing chemotherapy.
We Meet Global Standards
- Publication
- 22-06-2016
Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
- Publication
- 31-03-2017
Long‑term outcome of diffuse large B‑cell lymphoma: Impact of biosimilar rituximab and radiation
- Publication
- 13-01-2017
Safety and Efficacy of an Anti‑CD20 Monoclonal Antibody (Reditux) In Indian Patients with Seropositive Rheumatoid Arthritis
- Publication
- 25-03-2022